Market Research Logo

Anthrax - Pipeline Review, H2 2018

Anthrax - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2018, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 20, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Anthrax - Overview
Anthrax - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anthrax - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anthrax - Companies Involved in Therapeutics Development
Altimmune Inc
Aphios Corp
Aradigm Corp
BlueWillow Biologics Inc
Companhia Industrial Produtora de Antibioticos SA
Crestone Inc
Dynavax Technologies Corp
Emergent BioSolutions Inc
GC Pharma
Hawaii Biotech Inc
iBio Inc
iNtRON Biotechnology Inc
Pfenex Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
VLP Biotech Inc
Anthrax - Drug Profiles
anthrax (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax + plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-7909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPN-1311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPX-Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DV-230F - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-1109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GreAnPla - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GREANX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasoshield - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit Furin for Anthrax and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Px-563L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
raxibacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzymes to Disrupt Bacterial Cell Wall for Inhalational Anthrax Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RiVax + SGX-204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rPA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPA-563 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections and Bone Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SparVax-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
Mar 12, 2018: Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
Dec 11, 2017: Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial
Jun 19, 2017: NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine
Mar 28, 2017: Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield
Aug 08, 2016: Pfenex Announces Positive Anthrax Vaccine Study Results
Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines
Aug 17, 2015: Pfenex Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine
Mar 24, 2015: Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine
Jan 28, 2015: Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines
Dec 29, 2014: Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data
Dec 22, 2014: Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L
Oct 21, 2014: Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge with Rapid Acting, Single Dose Vaccine
Sep 08, 2014: Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine
Apr 01, 2014: Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies
Feb 04, 2014: Hawaii Biotech Awarded Anthrax Anti-toxin Grant By National Institute Of Allergy And Infectious Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anthrax, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Anthrax - Pipeline by Altimmune Inc, H2 2018
Anthrax - Pipeline by Aphios Corp, H2 2018
Anthrax - Pipeline by Aradigm Corp, H2 2018
Anthrax - Pipeline by BlueWillow Biologics Inc, H2 2018
Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2018
Anthrax - Pipeline by Crestone Inc, H2 2018
Anthrax - Pipeline by Dynavax Technologies Corp, H2 2018
Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2018
Anthrax - Pipeline by GC Pharma, H2 2018
Anthrax - Pipeline by Hawaii Biotech Inc, H2 2018
Anthrax - Pipeline by iBio Inc, H2 2018
Anthrax - Pipeline by iNtRON Biotechnology Inc, H2 2018
Anthrax - Pipeline by Pfenex Inc, H2 2018
Anthrax - Pipeline by Protein Potential LLC, H2 2018
Anthrax - Pipeline by ProThera Biologics Inc, H2 2018
Anthrax - Pipeline by Soligenix Inc, H2 2018
Anthrax - Pipeline by Syntiron LLC, H2 2018
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018
Anthrax - Pipeline by VLP Biotech Inc, H2 2018
Anthrax - Dormant Projects, H2 2018
Anthrax - Dormant Projects, H2 2018 (Contd..1), H2 2018
Anthrax - Dormant Projects, H2 2018 (Contd..2), H2 2018
Anthrax - Dormant Projects, H2 2018 (Contd..3), H2 2018
Anthrax - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Anthrax, H2 2018 11
Number of Products under Development by Companies, H2 2018 12
Number of Products under Development by Universities/Institutes, H2 2018 14
Number of Products by Top 10 Targets, H2 2018 18
Number of Products by Stage and Top 10 Targets, H2 2018 18
Number of Products by Top 10 Mechanism of Actions, H2 2018 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 20
Number of Products by Routes of Administration, H2 2018 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2018 23
Number of Products by Top 10 Molecule Types, H2 2018 25
Number of Products by Stage and Top 10 Molecule Types, H2 2018 25

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report